Vitura Health Q1 revenue rises to start FY27
- Vitura Health delivered first-quarter FY27 financial performance ahead of internal expectations across revenue, EBITDA, and operational expenditure.
- The announcement left the market unchanged, with the stock closing at the previous price point of $0.019.
- Growth was driven by strong demand across digital platforms and a new corporate growth strategy focused on disciplined execution.
Vitura Health (ASX:VIT) delivered a strong start to the first quarter of FY27, generating revenue growth of $1.7 million, or 4.8% against the previous corresponding period.
The top-line performance came ahead of prior market expectations following operational momentum across the business.
The company stated that the board has endorsed a Three Horizon Plan designed to establish a scalable foundation for sustainable long-term growth.
Vitura's CEO Justin James said, "Our priorities are clear with execution and profitability being front and centre. The company’s strategic plan addressing our core business, emerging growth opportunities and future thinking is also now being rolled out across the organisation."
Earnings before interest, taxes, depreciation, and amortisation rose by $1 million or 197.5%, while operational expenditure fell by $685,000 or 9.5% relative to the prior corresponding period.
Work is now underway on the first horizon of the growth plan, focusing on distribution capabilities, expense discipline, and system enhancements over the next 12 to 18 months.
Following the announcement, the Vitura Health share price was unchanged at $0.019.
The business operates digital health assets, including the Candor consumer consultation service and the Canview healthcare platform.
Recent expansion efforts have also incorporated telehealth services through Doctors on Demand alongside growing B2B and B2C operational pipelines.
